Business

Moderna announced on Friday that the Food and Drug Administration has postponed the approval of its respiratory syncytial virus (RSV) vaccine to the end of May due to what they described as “administrative constraints” within the agency. The decision, which was anticipated to be made on Sunday, has left investors on edge as they await
0 Comments
Oddity Tech, a newly public Israeli cosmetics platform, has defied expectations by exceeding first-quarter results. Using artificial intelligence to develop innovative beauty products, Oddity reported earnings per share of 61 cents compared to the expected 49 cents. Additionally, revenue reached $211.63 million, surpassing the projected $205 million. This remarkable performance showcases the company’s potential in
0 Comments
Equinox, a high-end fitness chain, has recently announced the launch of one of the world’s most expensive gym memberships — a $40,000-per-year program called “Optimize by Equinox.” This exclusive program, created in partnership with lab-test startup Function Health, aims to enhance overall health and longevity through personalized health plans that encompass a wide range of
0 Comments
Amgen’s stock saw a significant increase of over 12% after revealing positive initial data on its innovative weight loss injection, MariTide. This announcement sparked concerns among investors regarding new competition in the rapidly expanding weight loss drug market. The news led to a decline in the stock prices of Novo Nordisk and Eli Lilly, key
0 Comments
“Roundball Rock,” composed by John Tesh, is considered one of the greatest theme songs for TV sports, particularly for National Basketball Association games on NBC. The nostalgic association that NBA fans have with this tune is unparalleled, as it brings back memories of an era defined by Michael Jordan’s dominance, the Chicago Bulls’ success, and
0 Comments
The Federal Trade Commission has taken a bold step in challenging hundreds of alleged “junk” patents held by pharmaceutical companies for 20 brand-name drugs. These companies, including Novo Nordisk, AstraZeneca, Boehringer Ingelheim, and others, have been warned about improperly listed drug patents, particularly for medications related to Type 2 diabetes, asthma, and COPD. The practice
0 Comments